August 10, 2018 10:55 AM EDT

After mixed pipeline updates, RegenXBio to raise $175M in offering; BioElectron closes $40M to prep late-stage mitochondrial drug

Brittany Meiling

→ Just a couple days after announcing some mixed pipeline updates that yo-yoed the stock, gene therapy company RegenXBio $RGNX is trotting out news …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After mixed pipeline updates, RegenXBio to raise $175M in offering; BioElectron closes $40M to prep late-stage mitochondrial drug

Brittany Meiling

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Exclusive: Florida cancer biotech raises $100M Series A

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

David Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field

Af­ter mixed pipeline up­dates, Re­genXBio to raise $175M in of­fer­ing; Bio­Elec­tron clos­es $40M to prep late-stage mi­to­chon­dr­i­al drug

Brittany Meiling

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

After mixed pipeline updates, RegenXBio to raise $175M in offering; BioElectron closes $40M to prep late-stage mitochondrial drug

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Exclusive: Florida cancer biotech raises $100M Series A

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

David Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field